An interventional study of SPIN-CHAT Program in Scleroderma, Scleroderma, Systemic and Systemic Sclerosis, sponsored by Lady Davis Institute. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-01.
Sponsored by Lady Davis Institute · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Scleroderma, Diffuse with a site in Canada — 5 open to participants now, 8 under way, 2 of them phase 3. Scleroderma, Diffuse · Canada.
Among the 34 studies in Scleroderma, Diffuse with a site in Canada, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2020, is one of 11 with no phase, and was the 21st registered.
310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.
Browse Scleroderma, Diffuse studies →5 of the 34 studies in Scleroderma, Diffuse with a site in Canada are open now. Recruiting first, the newest first:
Allogene Therapeutics · Sites in Canada, United States
Ages 18–74
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Primus Pharmaceuticals · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 40–80 · Healthy volunteers
The Hospital for Sick Children · Sites in Canada
Ages up to 18
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 5
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 38 across 227 interventional studies indexed under Scleroderma, Diffuse.
Median enrollment 82 across the 32 interventional studies, 42 across the 2 observational. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 34 have an industry lead sponsor. The 10 most frequent:
Lady Davis Institute is the lead sponsor of 46 studies on the registry; 7 are open to participants now.
Lady Davis Institute has 9 studies filed under Scleroderma, Diffuse — fewer than ten, so there is no comparison to draw.
4 of the studies in Scleroderma, Diffuse with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06847750The Hospital for Sick ChildrenElastography Ultrasound in Localized Scleroderma (Morphea) Study | 2026-12-31 |
| NCT03800017University of British ColumbiaSkeletal Muscle Function in Interstitial Lung Disease | 2026-12-31 |
| NCT06256575Primus PharmaceuticalsStudy of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis | 2027-07-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Scleroderma, Diffuse with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Contagious disease outbreaks, such as the coronavirus disease 2019 (COVID-19) outbreak, and associated restrictions to prevent spread can lead to negative psychological outcomes, including loneliness, depression, and anxiety, particularly in vulnerable populations at risk due to existing medical conditions. To date, no randomized controlled trials have tested interventions to reduce mental health consequences of contagious disease outbreaks.
Systemic sclerosis (SSc; scleroderma) is a rare, chronic, autoimmune disease characterized by vasculopathy and excessive collagen production. Systemic Sclerosis can affect multiple organ systems, including the skin, lungs, gastrointestinal tract, and heart. Many people with scleroderma are at risk of serious complications from COVID-19 if infected due to lung involvement (> 40% have interstitial lung disease) and common use of immunosuppressant drugs.
The objective of The Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial is to evaluate a videoconference-based intervention designed to improve symptoms of anxiety and other mental health outcomes among individuals with systemic sclerosis at risk of poor mental health during the COVID-19 pandemic. The trial is a pragmatic randomized controlled trial that will be conducted using an existing cohort of systemic sclerosis patients. We will use a partially nested design to reflect dependence between individuals in training groups but not in the waitlist control. The SPIN-CHAT Program includes activity engagement, education on strategies to support mental health, and mutual participant support.
Background: Social distancing and movement restrictions during contagious disease outbreaks are necessary to reduce spread but can lead to negative social and psychological outcomes, including loneliness, depression, and anxiety, particularly in vulnerable populations. An online survey that used snowball sampling techniques and collected data from 1210 respondents from 194 cities in China in January-February 2020 found that over 50% rated the psychological impact of the coronavirus disease 2019 (COVID-19) outbreak as moderate or severe. Symptoms of anxiety were rated as the most common psychological problem. Self-reported poor physical health status and the presence of a chronic illness were associated with symptoms of depression and anxiety.
Systemic sclerosis (SSc; scleroderma) is a rare, chronic, autoimmune disease characterized by vasculopathy and excessive collagen production. Onset typically occurs between the ages of 30 and 50 years, and approximately 80% of people with SSc are women. SSc can affect multiple organ systems, including the skin, lungs, gastrointestinal tract, and heart. Disease presentation is extremely heterogeneous, and the course of the disease is highly unpredictable. People with SSc commonly experience hand function and mobility limitations, pain, fatigue, sleep problems, pruritus, symptoms of depression, and body image distress from disfiguring aspects (e.g., skin tightening, pigment changes, hand contractures, telangiectasias). Many people with SSc are at risk of serious complications from COVID-19 if infected due to lung involvement (> 40% have interstitial lung disease) and common use of immunosuppressant drugs.
The Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program is a group videoconference-based intervention designed to improve symptoms of anxiety and other mental health outcomes among individuals with SSc at risk of poor mental health during the COVID-19 pandemic. The primary objective of the SPIN-CHAT Trial is to evaluate the effect of the program compared to waitlist control on patient reported symptoms of anxiety as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0 scores.
Recruitment and Enrolment: SPIN is a collaboration of SSc researchers, health care providers, people living with SSc, and patient organizations from Canada, the United States, Europe, Mexico and Australia that has assembled a large multinational patient cohort to collect longitudinal data on patient-reported outcomes in SSc and as a framework for embedding RCTs of e-health interventions. SPIN Cohort participants complete online assessments upon enrolment and at 3-month intervals. To date, over 2000 SSc patients from 47 centres have been enrolled in SPIN's web-based cohort (currently approximately 1800 active participants).
SPIN Cohort participants will be invited by email and by popups to enrol in the SPIN-COVID-19 Cohort, a sub-cohort of the SPIN Cohort. Additionally, recruitment announcements for the SPIN-COVID-19 Cohort will be posted on SPIN's social media and distributed through our patient organization partners. All SPIN-COVID-19 Cohort participants will be invited to complete measures at baseline and every two weeks for the duration of the COVID-19 pandemic. They will receive email reminders to complete bi-weekly follow-up assessments.
Participants in the SPIN-COVID-19 Cohort eligible for the SPIN-CHAT Trial will be provided with a brief description of the trial in the SPIN-COVID-19 Qualtrics platform and will be asked if they would be interested in participating in the trial. Those who express interest will be provided with an online version of the trial consent form, which they can also download, and will be given the options of (1) consenting to participate; (2) declining participation; or (3) requesting that a member of SPIN's research team call them to answer questions they have about participating in the trial before consenting.
Methods: The SPIN-CHAT Trial is a pragmatic, two-arm partially nested RCT (PN-RCT) that will be conducted using the SPIN-COVID-19 Cohort. Pragmatic RCTs are conducted to replicate real-world delivery of interventions as much as possible and support decisions on whether interventions should be provided in practice. The trial will be a PN-RCT because participants randomised to the intervention arm will be clustered into intervention groups, and members of each intervention group will interact during videoconference sessions; participants randomly assigned to the waitlist control will not be clustered and will only complete trial measures.
Random Selection and Allocation: SPIN-COVID-19 Cohort participants who provide consent for participation will be entered into different pools based on their availabilities and taking into consideration time zone differences. Once there are enough participants to complete an intervention group and assign an equal number of participants to waitlist control, SPIN personnel will provide the external service with an anonymised list of participants (only identification numbers will be provided) who could participate in an intervention group based on language and day and time availabilities. For each intervention group and waitlist control pairing, the service will randomly select 16 participants from the pool of enroled participants available based on language, day, and time and will randomly allocate 8 to the intervention group and 8 to the waitlist group using block randomization.This process will be repeated until trial enrolment is complete. One intervention and waitlist control pairing will include 18 participants (9 intervention, 9 waitlist) to accommodate the total number that we anticipate randomizing.
Intervention and Comparator: Mental health outcomes, including anxiety, among people in quarantine are associated with modifiable factors such as degree of isolation, boredom, and ability to manage worry and anxiety. In addition to psychological strategies, including worry reduction and meditative exercises, exercise has been shown to reduce anxiety. Among older adults, where isolation is a common challenge, activity and social engagement are commonly used to address loneliness and feelings of isolation. Recommendations for the World Health Organization and major national public health organizations for managing mental health during COVID-19 emphasize setting and following a routine, managing information sources and quantity, staying connected with others, and finding a way to be physically active.
The SPIN-CHAT Program is a brief group videoconference intervention that was developed based on best-practice principles for managing anxiety and worry, recommendations for maintaining mental health during COVID-19, and input from the SPIN COVID-19 Patient Advisory Team. Educational segments in each session will be delivered by a research team member with experience and training related to the topic. Leisure activities that will be done at the start of each session will include games (e.g., Pictionary, charades), creative activities (e.g., roll-a-story), cultural activities (e.g., virtual museum tours), social activities (e.g., share your favourite recipe). In the healthy information management and social connection segment, strategies will be provided and discussion will be facilitated on how to stay informed via accurate information sources while avoiding sensationalist and other non-helpful information. Information on using simple (e.g., phone) or more advanced technology (e.g., group videoconferencing) to stay connected will be discussed, along with strategies for connecting regularly with others. The managing worry segments will include an overview of worry, including what it is, the difference between helpful and harmful anxiety or worry, how to identify triggers of worry, and strategies to manage worry, including identifying different types of worrying, using worry journals, worry postponement, and worry time. Exercises will be done with the group to illustrate techniques. In the relaxation segments, an introduction to the purpose of relaxation techniques will be presented, and participants will be guided through brief breathing, mindfulness, and visualization exercises.
The physical activity segments will include an overview of the physical and psychosocial benefits of physical activity for maintenance of health for chronic disease management, including mental health during the COVID-19 pandemic; movement guidelines to ensure safety; and how to monitor daily physical activity. Participants will be guided through movement options for the home-based setting, including warm-ups, aerobic, and strength activities. Behaviour change techniques to foster building the habit of moving more at home will be taught, including goal-setting, scheduling, addressing barriers, and building social support.
Activity engagement sessions will be guided by the leisure education content model. Sessions will involve interactive group discussion about the benefits of leisure engagement for persons with SSc, addressing physical, social, emotional, intellectual and spiritual realms of health and wellbeing. Sessions will explore barriers to leisure for persons with SSc and includes tips for finding leisure resources within the participants' own homes, both in-person and online.
Sample Size: Effects of short anxiety-focused interventions in post-disaster settings are between 0.40 and 0.80 standardized mean difference (SMD). This is larger than estimated minimally important difference for the PROMIS Anxiety 4a v1.0 score (SMD = 0.23 to 0.34 SMD). For an assumed effect size of SMD = 0.50, a two-tailed test with alpha = 0.05, and an intra-class correlation coefficient (ICC) of 0.05, N=146 provides 80% power or greater for our primary outcome, PROMIS Anxiety 4a v1.0; assuming 10% dropout, we will recruit 162 participants (81 in 10 SPIN-CHAT groups; 81 waitlist). We believe that this is a conservative power and sample size estimate. First, in cluster RCTs, ICC values for individual patient outcomes are typically lower than our 0.05 estimate. If the true ICC is lower than our 0.05 estimate, this will result in greater power than estimated. Second, there has been no loss to follow-up in the feasibility trial or initial waves of our full-scale trial of the videoconference-based SPIN support group leader program, which has a similar design. Thus, we believe that a 10% loss to follow-up may be conservative.
Data Analysis: Analyses will be conducted by a statistician blind to trial arm allocation. For the primary outcome analysis, we will use an intent-to-treat analysis that compares all patients randomly assigned to the SPIN-CHAT Program to all patients assigned to the waitlist control. The intervention effect at 4 weeks will be estimated using a linear mixed model, adjusted for baseline PROMIS Anxiety 4a v1.0 scores. The model will include a random effect to account for clustering of participants in the training groups, but not for participants in the waitlist control arm, because there is no clustering in the control arm. We will investigate the effects of missing data using multiple imputation. As a secondary analysis, we will additionally adjust for age, sex, baseline loneliness, baseline boredom, and baseline physical activity. Analyses of secondary outcomes will similarly be done (1) controlling for baseline scores only and (2) controlling for baseline scores, age, sex, and other key baseline measures. Statistical significance for all analyses will be determined based on two-sided α = 0.05. In addition, we will use complier-average causal effect analysis to estimate effects among patients who use the intervention compared to similar patients in the waitlist arm of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.
Other: SPIN-CHAT Program
Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.
Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0
The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.
Time frame: 4-weeks post-randomization
Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0
The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.
Time frame: 10-weeks post-randomization
Depression Symptoms: Patient Health Questionnaire (PHQ-8)
PHQ-8 items measure depressive symptoms over the last 2 weeks on a 4-point scale, ranging from 0 (not at all) to 3 (nearly every day) with higher scores (range 0 to 24) indicating more depressive symptoms. The PHQ-8 performs equivalently to the PHQ-9, which has been shown to be a valid measure of depressive symptoms in patients with scleroderma.
Time frame: 4-weeks post-randomization, 10-weeks post-randomization
Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)
The 6-item ULS-6 is a short version of the 20-item ULS, which is designed to assess subjective feelings of loneliness and social isolation. Respondents indicate the degree to which feelings described in each item apply to them. Items are scored on a 4-point scale from 0 (never) to 3 (often); total scores range from 0 to 18 with higher scores indicating greater loneliness.
Time frame: 4-weeks post-randomization, 10-weeks post-randomization
Boredom: Multidimensional State Boredom Scale (MSBS-8)
The full MSBS is a 29-item measure of state boredom with items on five factors that load onto a single higher-order factor. The 8-item MSBS is a short version with scores that correlate very closely to scores from the full MSBS (r = 0.96) Item responses are on a 7-point Likert-type scale from 1 (strongly disagree) to 7 (strongly agree) and assess the degree to which each item reflects the respondant's experience currently. Total scores range from 8 to 56 with higher scores reflecting greater boredom.
Time frame: 4-weeks post-randomization, 10-weeks post-randomization
Physical Activity: International Physical Activity Questionnaire - Modified for the Elderly (IPAQ-E)
The 4-item IPAQ-E is a short-form version of the full IPAQ designed to assess physical activity over the last week, including time spent sitting, walking, and in moderate and vigorous physical activity. Compared to other short-form versions of the IPAQ, the IPAQ-E has examples of exercise specific to older adults. The unit of measure is MET(metabolic equivalent turnover)-minutes per week, which larger values meaning greater activity.
Time frame: 4-weeks post-randomization, 10-weeks post-randomization
Adverse Effects
Adverse Effects will be assessed by ongoing monitoring during the trial and by asking participants post-intervention to describe any adverse experiences or outcomes that may have occurred.
Time frame: 4-weeks post-randomization, 10-weeks post-randomization
Fear: COVID-19 Fears Questionnaire for Chronic Medical Conditions
The COVID-19 Fears Questionnaire for Chronic Medical Conditions is a 10-item scale that ask participants to rate, on a typical day in the last week, how much they were afraid from "not at all" to "extremely" about aspects of COVID-19. Items are scored on a 5-point scale (range 1-5), total scores range from 10 to 50. Higher scores represent greater fear. The scale has been validated among people with scleroderma.
Time frame: 4-weeks post-randomization, 10-weeks post-randomization
From April 9, 2020 to April 27, 2020, we recruited participants into a new SPIN COVID-19 Cohort internationally via social media announcements and from an existing systemic sclerosis cohort (the SPIN cohort). Ongoing SPIN Cohort participants were invited to enrol by email and via notices during regular SPIN Cohort assessments. Recruitment announcements were posted via social media and through patient organisation partners.
| Milestone | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| Started | 86 | 86 |
| Completed measures post-intervention | 78 | 83 |
| Completed | 75 | 76 |
| Not completed | 11 | 10 |
The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.
| T-score | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0 | 56.9 ± 7.6 | 58.8 ± 6.3 |
The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.
| T-score | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0 | 55.1 ± 6.7 | 58.2 ± 8.2 |
PHQ-8 items measure depressive symptoms over the last 2 weeks on a 4-point scale, ranging from 0 (not at all) to 3 (nearly every day) with higher scores (range 0 to 24) indicating more depressive symptoms. The PHQ-8 performs equivalently to the PHQ-9, which has been shown to be a valid measure of depressive symptoms in patients with scleroderma.
| score on a scale | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| 4-weeks post-randomization | 6.6 ± 4.6 | 6.9 ± 5.4 |
| 10-weeks post-randomization | 5.5 ± 4.2 | 7.3 ± 5.9 |
The 6-item ULS-6 is a short version of the 20-item ULS, which is designed to assess subjective feelings of loneliness and social isolation. Respondents indicate the degree to which feelings described in each item apply to them. Items are scored on a 4-point scale from 0 (never) to 3 (often); total scores range from 0 to 18 with higher scores indicating greater loneliness.
| score on a scale | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| 4-weeks post-randomization | 8.6 ± 3.7 | 9.5 ± 3.6 |
| 10-weeks post-randomization | 8.6 ± 3.4 | 9.4 ± 3.8 |
The full MSBS is a 29-item measure of state boredom with items on five factors that load onto a single higher-order factor. The 8-item MSBS is a short version with scores that correlate very closely to scores from the full MSBS (r = 0.96) Item responses are on a 7-point Likert-type scale from 1 (strongly disagree) to 7 (strongly agree) and assess the degree to which each item reflects the respondant's experience currently. Total scores range from 8 to 56 with higher scores reflecting greater boredom.
| score on a scale | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| 4-weeks post-randomization | 28.6 ± 10.6 | 31.1 ± 10.8 |
| 10-weeks post-randomization | 26.7 ± 10.8 | 29.3 ± 11.2 |
The 4-item IPAQ-E is a short-form version of the full IPAQ designed to assess physical activity over the last week, including time spent sitting, walking, and in moderate and vigorous physical activity. Compared to other short-form versions of the IPAQ, the IPAQ-E has examples of exercise specific to older adults. The unit of measure is MET(metabolic equivalent turnover)-minutes per week, which larger values meaning greater activity.
| MET-minutes per week | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| 4-weeks post-randomization | 2984 ± 2734 | 2769 ± 3198 |
| 10-weeks post-randomization | 2737 ± 2255 | 3171 ± 3475 |
Adverse Effects will be assessed by ongoing monitoring during the trial and by asking participants post-intervention to describe any adverse experiences or outcomes that may have occurred.
| adverse events | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| 4-weeks post-randomization | 0 | 0 |
| 10-weeks post-randomization | 0 | 0 |
The COVID-19 Fears Questionnaire for Chronic Medical Conditions is a 10-item scale that ask participants to rate, on a typical day in the last week, how much they were afraid from "not at all" to "extremely" about aspects of COVID-19. Items are scored on a 5-point scale (range 1-5), total scores range from 10 to 50. Higher scores represent greater fear. The scale has been validated among people with scleroderma.
| score on a scale | SPIN-CHAT: Videoconference Intervention | Wait-list Control |
|---|---|---|
| 4-weeks post-randomization | 26.3 ± 9.4 | 28.7 ± 10.3 |
| 10-weeks post-randomization | 25.4 ± 10.6 | 27.1 ± 10.7 |
Collected over Assessed throughout the intervention period (i.e. 4-weeks post-randomization), and during the post-trial assessment period (i.e. 10-weeks post-randomization).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPIN-CHAT: Videoconference Intervention | 0/86 (0%) | 0/86 (0%) | 0/86 (0%) |
| Wait-list Control | 0/86 (0%) | 0/86 (0%) | 0/86 (0%) |
| Age, Continuous(years) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| Mean | 56.0 ± 11.9 | 54.0 ± 10.9 | 55.0 ± 11.4 |
| Sex: Female, Male(Participants) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| Female | 81 | 81 | 162 |
| Male | 5 | 5 | 10 |
| Race/Ethnicity, Customized(Participants) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| White | 73 | 63 | 136 |
| Black | 4 | 8 | 12 |
| Other | 9 | 15 | 24 |
| Region of Enrollment(Participants) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| Canada | 27 | 23 | 50 |
| United States | 27 | 34 | 61 |
| France | 15 | 14 | 29 |
| United Kingdom | 7 | 5 | 12 |
| Australia | 6 | 5 | 11 |
| Germany | 0 | 2 | 2 |
| India | 0 | 1 | 1 |
| Netherlands | 1 | 0 | 1 |
| New Zealand | 1 | 0 | 1 |
| Nicaragua | 0 | 1 | 1 |
| Norway | 0 | 1 | 1 |
| Philippines | 2 | 0 | 2 |
| Education(years) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| Mean | 15.4 ± 3.4 | 16.4 ± 3.3 | 15.9 ± 3.4 |
| Married or living as married(Participants) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| Count of participants | 53 | 51 | 104 |
| Living alone(Participants) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| Count of participants | 13 | 21 | 34 |
| Working part-time or full-time(Participants) | SPIN-CHAT: Videoconference Intervention | Wait-list Control | Total |
|---|---|---|---|
| Count of participants | 37 | 29 | 66 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Upon request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 12 months after the collection of the primary outcome
Access criteria: Approval of proposed purpose for data access
Ran from Apr 2020 to primary completion in Jun 2020, 1 month.
Results were first posted in Feb 2023, 2 years 7 months after primary completion.
Of 51 non-industry interventional studies with no phase under Scleroderma, Diffuse, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 1 month is below that.
Counting every sponsor, half of 53 studies reached it within 16 months; a quarter within 4 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lady Davis Institute